Clinical Trial

A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD Patients

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 11, 2025 (before its estimated September 25, 2025 completion). Its status may not reflect the trial's current state.
Summary
The study will be a single center, double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, PK and PD of AP303 following 2-week oral administration to Diabetic Kidney Disease patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-29.
Status change: Not Yet Recruiting → Recruiting 2025-09-05
Trial Details
NCT Number NCT06666283
Lead Sponsor Alebund Pharmaceuticals
Conditions Diabetic Kidney Disease
Enrollment 18 participants
Start Date 2025-02-27
Primary Completion 2025-09-25 (estimated)
Study Completion 2025-09-25 (estimated)
Updated on ClinicalTrials.gov 2025-09-11